Business
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL
About this update from Surrozen, Inc.
[{"type":"text","content":"Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted Protein Degradation technologies resulting in robust Wnt signal activation in bispecific antibodies based on the Company's SWEETS technology platform SOUTH SAN FRANCISCO, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2024 financial results and business updates. “We made significant progress in the second quarter with accomplishment of key milestones including dosing the first patient in the SZN-043 Phase 1b trial, presenting first-in-human data from the SZN-043 Phase 1a trial at EASL and publishing new information regarding the promise of our proprietary SWEETS platform,” said Craig Parker, President and Chief Executive Officer of Surrozen. “Surrozen is focused on transforming the treatment of severe diseases of the liver and eye, and we look forward to proof-of-concept data from the SZN-043 Phase 1b clinical trial in the first half of 2025.” Research and Development Pipeline Highlights SZN-043Surrozen is developing SZN-043 for severe liver disease with an initial focus in severe alcohol-associated hepatitis. Clinical Development Milestones and Medical Meeting Presentation Enrollment initiated and ongoing in Phase 1b trial; proof-of-concept data is anticipated in the first half of 2025Presented Phase 1a trial results at 2024 European Association for the Study of the Liver (EASL) in June 2024 (LINK: HERE) Treatment with SZN-043 was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosisResults demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver Research Programs Publications Surrozen published study in eLife (LINK: HERE) describing development of two new ASGR bispecific antibodies that resulted in a robust and cell specific boost to Wnt-signaling through protein degradation technologies These ASGR-targeted SWEETS (Surrozen Wnt Signal Enhancer Engineered for Tissue Specificity) molecules represent a unique targeted protein...